Elan has chosen Robert Ingram, former vice chairman of GlaxoSmithKline's pharmaceutical operations, to serve as chairman of the board starting Jan. 26, 2011. He will take over for Kyran McLaughlin, who earlier this year announced his intention to leave. Ingram "has a proven track record of successful leadership and a deep understanding of the [pharmaceutical] industry overall," McLaughlin said.

Related Summaries